Consequently, C1 patients might require the combination treatment discussed earlier, integrating radiotherapy with drugs blocking TIM3 and PD-1, to stimulate the tumor’s internal immune response, activate T-cells, and kill tumor cells (Kim et al., 2017). Here, PDCD1 is linked to neoplasm.